Oncology Nurse Edition Editorial and Publishing Staff April 2011

Article

EDITORIAL AND PUBLISHING STAFF

Cindy FlaumVP, Clinical Publishing

Rachel WarrenEditorial Director

Anne LandryExecutive Editor

Nancy BittekerDirector, Design & Digital Production

Meg StrizverProduction Manager

Amy Birnbach
Group Publisher, Oncology

Sarah MifsudDigital Sales

William Markowitz, RPhPublishing Director

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Related Content
Induction chemotherapy may allow investigators to biologically select patients with a favorable prognosis who benefit most from chemoradiotherapy.

Chemoradiation May Convert Unresectable Pancreatic Cancers for Resection

Russ Conroy
August 21st 2025
Article
Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 21st 2025
Podcast
No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.

Consolidative Thoracic Radiotherapy Displays Safety, Efficacy in ES-SCLC

Roman Fabbricatore
August 21st 2025
Article
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 21st 2025
Podcast
The primary end point of the trial was PFS. Secondary end points included OS, ORR, and the toxicity profile of nivolumab with carboplatin/cisplatin and etoposide.

Nivolumab Plus Chemo Improved OS and PFS in Front-Line ES-SCLC

Tim Cortese
August 21st 2025
Article
Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Emotional Distress May Confer Worse Immunotherapy Outcomes in NSCLC

Russ Conroy
August 21st 2025
Article